312 related articles for article (PubMed ID: 19540068)
21. High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity.
Rishi A; Rollins M; Ahmed KA; Hunt DC; Sarkar P; Fernandez DC; Hoffman MS; Apte SM; Shahzad MMK; Chon HS; Chern JY; Wenham RM; Montejo ME
Gynecol Oncol; 2020 Feb; 156(2):349-356. PubMed ID: 31771865
[TBL] [Abstract][Full Text] [Related]
22. [Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
Qian W; Zhu G; Ji Q; Guo Y; Wang Y; Wang Y
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):217-22. PubMed ID: 24785284
[TBL] [Abstract][Full Text] [Related]
23. Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma.
Refaat T; Choi M; Thomas TO; Bacchus I; Agulnik M; Pelzer HJ; Mellott AL; Rademaker AW; Liu D; Sathiaseelan V; Mittal BB
Am J Clin Oncol; 2015 Dec; 38(6):588-94. PubMed ID: 24136140
[TBL] [Abstract][Full Text] [Related]
24. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure.
Frank SJ; Rosenthal DI; Petsuksiri J; Ang KK; Morrison WH; Weber RS; Glisson BS; Chao KS; Schwartz DL; Chronowski GM; El-Naggar AK; Garden AS
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1005-10. PubMed ID: 20207504
[TBL] [Abstract][Full Text] [Related]
25. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing.
Eisbruch A; Marsh LH; Dawson LA; Bradford CR; Teknos TN; Chepeha DB; Worden FP; Urba S; Lin A; Schipper MJ; Wolf GT
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):28-42. PubMed ID: 15093896
[TBL] [Abstract][Full Text] [Related]
26. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach.
Leclerc M; Maingon P; Hamoir M; Dalban C; Calais G; Nuyts S; Serre A; Grégoire V
Radiother Oncol; 2013 Mar; 106(3):333-40. PubMed ID: 23541643
[TBL] [Abstract][Full Text] [Related]
27. A comparison of outcomes using intensity-modulated radiation therapy and 3-dimensional conformal radiation therapy in treatment of oropharyngeal cancer.
Lohia S; Rajapurkar M; Nguyen SA; Sharma AK; Gillespie MB; Day TA
JAMA Otolaryngol Head Neck Surg; 2014 Apr; 140(4):331-7. PubMed ID: 24557509
[TBL] [Abstract][Full Text] [Related]
28. Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma.
Gunn GB; Blanchard P; Garden AS; Zhu XR; Fuller CD; Mohamed AS; Morrison WH; Phan J; Beadle BM; Skinner HD; Sturgis EM; Kies MS; Hutcheson KA; Rosenthal DI; Mohan R; Gillin MT; Frank SJ
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):360-367. PubMed ID: 27084653
[TBL] [Abstract][Full Text] [Related]
29. Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes.
Lok BH; Setton J; Caria N; Romanyshyn J; Wolden SL; Zelefsky MJ; Park J; Rowan N; Sherman EJ; Fury MG; Ho A; Pfister DG; Wong RJ; Shah JP; Kraus DH; Zhang Z; Schupak KD; Gelblum DY; Rao SD; Lee NY
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1851-7. PubMed ID: 21640497
[TBL] [Abstract][Full Text] [Related]
30. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma.
Lee NY; de Arruda FF; Puri DR; Wolden SL; Narayana A; Mechalakos J; Venkatraman ES; Kraus D; Shaha A; Shah JP; Pfister DG; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):966-74. PubMed ID: 17145527
[TBL] [Abstract][Full Text] [Related]
31. Cervical lymph node metastases from unknown primary cancer: a single-institution experience with intensity-modulated radiotherapy.
Villeneuve H; Després P; Fortin B; Filion E; Donath D; Soulières D; Guertin L; Ayad T; Christopoulos A; Nguyen-Tan PF
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1866-71. PubMed ID: 21497452
[TBL] [Abstract][Full Text] [Related]
32. Combination of p16 levels and pre-radiotherapy factors predicts outcome in patients treated for oropharyngeal carcinoma.
Bar-Ad V; Wang ZX; Leiby B; Tuluc M
J BUON; 2013; 18(4):982-8. PubMed ID: 24344027
[TBL] [Abstract][Full Text] [Related]
33. Definitive intensity-modulated radiotherapy concurrent with systemic therapy for oropharyngeal squamous cell carcinoma: Outcomes from an integrated regional Australian cancer centre.
Masoud Rahbari R; Winkley L; Hill J; Tahir AR; McKay M; Last A; Shakespeare TP; Dwyer P
J Med Imaging Radiat Oncol; 2016 Jun; 60(3):414-9. PubMed ID: 26786975
[TBL] [Abstract][Full Text] [Related]
34. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
35. Prospective functional outcomes in sequential population based cohorts of stage III/ IV oropharyngeal carcinoma patients treated with 3D conformal vs. intensity modulated radiotherapy.
Kerr P; Myers CL; Butler J; Alessa M; Lambert P; Cooke AL
J Otolaryngol Head Neck Surg; 2015 May; 44(1):17. PubMed ID: 25964113
[TBL] [Abstract][Full Text] [Related]
36. Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy.
Garden AS; Dong L; Morrison WH; Stugis EM; Glisson BS; Frank SJ; Beadle BM; Gunn GB; Schwartz DL; Kies MS; Weber RS; Ang KK; Rosenthal DI
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):941-7. PubMed ID: 22975604
[TBL] [Abstract][Full Text] [Related]
37. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.
Mitchell MP; Abboud M; Eng C; Beddar AS; Krishnan S; Delclos ME; Crane CH; Das P
Am J Clin Oncol; 2014 Oct; 37(5):461-6. PubMed ID: 23466576
[TBL] [Abstract][Full Text] [Related]
38. [Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma].
Zhao C; Han F; Lu LX; Huang SM; Lin CG; Deng XW; Lu TX; Cui NJ
Ai Zheng; 2004 Nov; 23(11 Suppl):1532-7. PubMed ID: 15566674
[TBL] [Abstract][Full Text] [Related]
39. IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer.
Zwicker F; Roeder F; Thieke C; Timke C; Münter MW; Huber PE; Debus J
Strahlenther Onkol; 2011 Jan; 187(1):32-8. PubMed ID: 21234529
[TBL] [Abstract][Full Text] [Related]
40. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
Klem ML; Mechalakos JG; Wolden SL; Zelefsky MJ; Singh B; Kraus D; Shaha A; Shah J; Pfister DG; Lee NY
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1100-7. PubMed ID: 17980501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
